Current followup strategies after radical prostatectomy: A survey of American Urological Association Urologists

被引:25
作者
Oh, J [1 ]
Colberg, JW [1 ]
Ornstein, DK [1 ]
Johnson, ET [1 ]
Chan, D [1 ]
Virgo, KS [1 ]
Johnson, FE [1 ]
机构
[1] Washington Univ, Sch Med,St Louis Univ Hlth Sci Ctr & Surg Serv, Dept Surg,John Cochran Vet Affairs Med Ctr, Div Urol Surg, St Louis, MO 63110 USA
关键词
prostatic neoplasms; prostatectomy; prostate; data collection;
D O I
10.1016/S0022-5347(01)61939-6
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Followup care of men who have undergone potentially curative surgical treatment for prostate cancer varies widely among clinicians. To determine current practice patterns we mailed a custom designed questionnaire to American and nonAmerican urologists who were American Urological Association (AUA) members. Materials and Methods: Surveys were mailed to a random sample of the approximately 12,000 AUA members, comprising 3,205 Americans and 1,262 nonAmericans. Evaluable surveys were returned by 760 American (24%) and 290 nonAmerican (23%) urologists. Our analysis is based on these 1,050 responses. Results: In generally healthy patients after radical prostatectomy for stages T1 to 2N0M0 and T3a to cN0M0 prostate cancer the most frequently recommended followup diagnostic tests included office visit with digital rectal examination, serum prostate specific antigen (PSA) and urinalysis. Although there is appreciable variation in the frequency of use of these methods, respondents generally recommended office visit with digital rectal examination, serum PSA and urinalysis every 3 months in year 1, every 6 months in years 2 to 5 and annually thereafter. Other tests, such as serum prostatic acid phosphatase, bone scan, and abdominal and pelvic computerized tomography and magnetic resonance imaging, are rarely recommended. Conclusions: Our survey provides information regarding current followup strategies recommended by AUA urologists after radical prostatectomy for stages T1 to 2N0M0 and T3a to cN0M0 disease. Office visits and digital rectal examination, urinalysis and PSA measurement are the main tools that urologists currently use. Although optimal strategy remains unknown, these data permit the rational design of clinical trials of alternate followup strategies based on actual current practice to answer this important question.
引用
收藏
页码:520 / 523
页数:4
相关论文
共 22 条
  • [1] Prospective evaluation of men with stage T1c adenocarcinoma of the prostate
    Carter, HB
    Sauvageot, J
    Walsh, PC
    Epstein, JI
    [J]. JOURNAL OF UROLOGY, 1997, 157 (06) : 2206 - 2209
  • [2] 5-YEAR TUMOR RECURRENCE RATES AFTER ANATOMICAL RADICAL RETROPUBIC PROSTATECTOMY FOR PROSTATE-CANCER
    CATALONA, WJ
    SMITH, DS
    [J]. JOURNAL OF UROLOGY, 1994, 152 (05) : 1837 - 1842
  • [3] Local recurrence after radical prostatectomy: Characteristics in size, location, and relationship to prostate-specific antigen and surgical margins
    Connolly, JA
    Shinohara, K
    Presti, JC
    Carroll, PR
    [J]. UROLOGY, 1996, 47 (02) : 225 - 231
  • [4] A MULTIVARIATE-ANALYSIS OF CLINICAL AND PATHOLOGICAL FACTORS THAT PREDICT FOR PROSTATE-SPECIFIC ANTIGEN FAILURE AFTER RADICAL PROSTATECTOMY FOR PROSTATE-CANCER
    DAMICO, AV
    WHITTINGTON, R
    MALKOWICZ, SB
    SCHULTZ, D
    SCHNALL, M
    TOMASZEWSKI, JE
    WEIN, A
    [J]. JOURNAL OF UROLOGY, 1995, 154 (01) : 131 - 138
  • [5] INTENSIVE DIAGNOSTIC FOLLOW-UP AFTER TREATMENT OF PRIMARY BREAST-CANCER - A RANDOMIZED TRIAL
    DELTURCO, MR
    PALLI, D
    CARIDDI, A
    CIATTO, S
    PACINI, P
    DISTANTE, V
    AZZINI, V
    BELSANTI, V
    BARTOLUCCI, R
    DICOSTANZO, F
    BERTUSI, M
    DANESE, S
    GIARDINA, G
    DAIUTO, G
    UCCELLO, V
    DELEO, G
    PUNZO, C
    GOSSO, P
    GRISO, C
    LOCATELLI, E
    MANSUTTI, M
    SANDRI, P
    MOLINO, AM
    SCHINCAGLIA, P
    TIENGHI, A
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (20): : 1593 - 1597
  • [6] DEVISSCHER AVM, 1994, ARCH OTOLARYNGOL, V120, P934
  • [7] FERGUSON JK, 1994, UROL CLIN N AM, V21, P677
  • [8] HUBEN RP, 1997, CANC PATIENT FOLLOW, P378
  • [9] HUMPHREY PA, 1993, CANCER-AM CANCER SOC, V71, P1821, DOI 10.1002/1097-0142(19930301)71:5<1821::AID-CNCR2820710517>3.0.CO
  • [10] 2-O